+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 24 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.

Age: 18Years +All GendersPhase 2
109 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
R

Actively Recruiting

Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.

Age: 18Years +All GendersPhase 2
53 locations
R

Actively Recruiting

Amblyopia is a common cause of reduced vision in one eye among children and young adults, affecting between 1% to 5% of this population. It often results from untreated differences in vision between the eyes or eye misalignment, and can impact various visual functions including depth perception and reading ability. Researchers are using a patient registry to collect real-world data on Luminopia, an FDA-approved device that offers a new dual action treatment for amblyopia, to understand how it is used by eye care professionals and its effects in everyday practice. This study observes patients who have been treated with Luminopia, a medical device that uses therapeutic software to stimulate vision in the affected eye. The registry collects clinical information over time without altering the standard care these patients receive. By gathering data at multiple points including 3, 6, 12, and 24 months, researchers aim to track changes in visual acuity, stereoacuity, treatment adherence, and treatment duration. Participants provide clinical data through their regular follow-up visits while undergoing Luminopia treatment. Researchers monitor vision improvements and durability of results after stopping treatment using standard clinical assessments. The study also analyzes outcomes based on factors like prior treatments, type and severity of amblyopia, age, and adherence levels. This comprehensive observation will help answer important scientific questions about the long-term real-world use of Luminopia therapy.

All AgesAll Genders
13 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
S

Actively Recruiting

Researchers are evaluating whether adding patients personal goals and concerns to the Collaborative Care Model CoCM can improve engagement and satisfaction for adults receiving behavioral health care for anxiety and depression disorders. The study compares enhanced collaborative care that uses a clinical decision support system CDSS with traditional collaborative care. The goal is to better align care with what matters most to patients and address limitations such as low motivation and loss of patients between referral and treatment. The study tests a new CDSS that includes an improved pre-visit questionnaire capturing patient goals and concerns, along with a dashboard displaying patient responses and clinical information within the electronic health record for use during visits. Patients complete questionnaires before appointments via a patient portal or tablet in the clinic. Clinicians and care managers use this information to better plan care and improve communication. Training and coaching are provided to care managers to support use of the CDSS and integrate patient preferences. Participants complete pre-visit questionnaires and are engaged in joint care planning with clinicians. Researchers track patient engagement from enrollment to discharge over about 3 to 4 months, along with patient and clinician satisfaction. Additional assessments include shared decision-making, communication, goal setting, and treatment response for depression and anxiety. The study is randomized with crossover design and collects data throughout the care period to evaluate impact on care quality and experience.

Age: 18Years - 100YearsAll GendersPhase Not Applicable
6 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations

1-10 of 24

1